Ceftolozane/Tazobactam as a carbapenem sparing strategy: Insights from patient level data.

Rogers, Benjamin (Primary Chief Investigator (PCI))

Centre for Inflammatory Disease Monash Health

Project: Research

Project Description

Retrospective cohort study of all patients with ESBL E. coli bacteraemia managed at Monash Health.

Status	Relinquished
Effective start/end date	1/01/19 → 9/12/19

Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection
Xie, O., Cisera, K., Taylor, L., Hughes, C. & Rogers, B., 30 Nov 2020, In: Annals of Clinical Microbiology and Antimicrobials. 19, 1, 9 p., 57.
Research output: Contribution to journal › Article › Research › peer-review

Open Access

7 Link opens in a new tab Citations (Scopus)